Ads
related to: sanofi- Dosing & Titration
Get Appropriate Dosing
for Patients. Learn More.
- Patient Brochure
Get Resources for Patients
Interested in this T2D Treatment
- Coverage Calculator
Check to See if Your
Patient is Covered for Treatment
- Clinical Trial Results
Understand Clinical Trial Data
& Findings. Learn More on Site.
- Dosing & Titration
Search results
The Next Humira? Insmed Catapults 113% On Its 'Very Attractive' Opportunity In Lung Disease.
Investor's Business Daily· 2 hours agoLeerink Partners analyst Joseph Schwartz compared the market potential for Insmed's brensocatib to...
FDA accepts Sanofi’s Sarclisa sBLA for priority review
Pharmaceutical Technology via Yahoo Finance· 9 hours agoThe US Food and Drug Administration (FDA) has accepted for priority review Sanofi's supplemental...
Sanofi's (SNY) Sarclisa sBLA Gets FDA's Priority Review Tag
Zacks via Yahoo Finance· 1 day agoThe FDA grants priority review to Sanofi's (SNY) sBLA for the Sarclisa combination regimen for...
Q3 2024 EPS Estimates for Sanofi (NASDAQ:SNY) Increased by Analyst
ETF DAILY NEWS· 7 days agoSanofi (NASDAQ:SNY – Free Report) – Research analysts at Zacks Research raised their Q3 2024 EPS estimates for Sanofi in a report released on Thursday, ...
Bristol Myers, Sanofi Liability in Hawaii Plavix Case Grows to $916 Million
Insurance Journal· 6 days agoA judge in Hawaii on Tuesday ordered Bristol Myers Squibb and Sanofi to pay more than $916 million...
Sanofi enters partnership to enhance drug development using AI
Pharmaceutical Technology via Yahoo Finance· 6 days agoSanofi has collaborated with Formation Bio and OpenAI to harness AI to expedite drug development. To...
Sanofi Drug Shows Promise in Asthma After Blood Disorder Success
Bloomberg· 6 days agoA Sanofi experimental drug showed promise in treating asthma, supporting the French drugmaker’s plan...
PNC Financial Services Group Inc. Sells 93,285 Shares of Sanofi (NASDAQ:SNY)
ETF DAILY NEWS· 3 days agoPNC Financial Services Group Inc. lowered its position in Sanofi (NASDAQ:SNY – Free Report) by 48.1% during the fourth quarter, Holdings Channel reports. The institutional ...
Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi
Yucaipa News Mirror· 4 days agoInhibrx, Inc. (Nasdaq: INBX) ("Inhibrx," or the "Company") announced that, at a special meeting (the "Special Meeting"), the Company's stockholders approved the sale to Sanofi
First Advanced Oral Treatment For Asthma - Sanofi's Investigational Drug Shows Potential
Benzinga via Yahoo Finance· 6 days agoWednesday, Sanofi SA (NASDAQ:SNY) reported results from the Phase 2 study of oral rilzabrutinib in...